{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:16:59Z","timestamp":1787987819623,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1002\/jps.21723","type":"journal-article","created":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T15:52:40Z","timestamp":1236873160000},"page":"4170-4190","source":"Crossref","is-referenced-by-count":25,"title":["Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: Cell accumulation and equilibrium dialysis studies"],"prefix":"10.1016","volume":"98","author":[{"given":"Naveed","family":"Shaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagdeep","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.21723_bb0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0015","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/jps.10501","article-title":"Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system","volume":"92","author":"Gursoy","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21723_bb0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/(SICI)1097-0215(19960103)65:1<74::AID-IJC13>3.0.CO;2-I","article-title":"Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters","volume":"65","author":"Buckingham","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1002\/jps.21723_bb0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bjc.1992.217","article-title":"Reversal of multidrug resistance by surfactants","volume":"66","author":"Woodcock","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1002\/jps.21723_bb0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1023\/A:1016033702220","article-title":"The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system","volume":"13","author":"Nerurkar","year":"1996","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.08.021","article-title":"Effect of excipients on breast cancer resistance protein substrate uptake activity","volume":"124","author":"Yamagata","year":"2007","journal-title":"J Control Release"},{"key":"10.1002\/jps.21723_bb0040","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/A:1012823120935","article-title":"Complete characterization of the human ABC gene family","volume":"33","author":"Dean","year":"2001","journal-title":"J Bioenerg Biomembr"},{"key":"10.1002\/jps.21723_bb0045","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15144-6","article-title":"Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes","volume":"28","author":"Choo","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.21723_bb0050","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.21723_bb0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/B:DRUG.0000026248.45084.21","article-title":"Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice","volume":"22","author":"Bardelmeijer","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1002\/jps.21723_bb0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00689043","article-title":"Taxol encapsulation in poly(epsilon-caprolactone) microspheres","volume":"36","author":"Dordunoo","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/jps.21723_bb0065","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1023\/A:1024418524688","article-title":"Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU58668: Physicochemical and opsonization properties","volume":"20","author":"Ameller","year":"2003","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0168-3659(02)00009-3","article-title":"Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery","volume":"82","author":"Kabanov","year":"2002","journal-title":"J Control Release"},{"key":"10.1002\/jps.21723_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0927-7765(99)00058-2","article-title":"Nano-engineering block copolymer aggregates for drug delivery","volume":"16","author":"Allen","year":"1999","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"10.1002\/jps.21723_bb0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0939-6411(02)00119-4","article-title":"Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by Caco-2 cells using low molecular weight methoxypolyethylene glycol-block-polycaprolactone diblock copolymers","volume":"54","author":"Zastre","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.21723_bb0085","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0022-3565(24)38781-6","article-title":"Pluronic P85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies","volume":"296","author":"Batrakova","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.21723_bb0090","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1023\/A:1018873702411","article-title":"Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers","volume":"16","author":"Miller","year":"1999","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i1.10","article-title":"Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers","volume":"19","author":"Kabanov","year":"2002","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1002\/jps.21723_bb0100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2004.09.002","article-title":"Distribution kinetics of a micelle-forming block copolymer Pluronic P85","volume":"100","author":"Batrakova","year":"2004","journal-title":"J Control Release"},{"key":"10.1002\/jps.21723_bb0105","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1023\/A:1018990706838","article-title":"Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers","volume":"16","author":"Batrakova","year":"1999","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0110","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1023\/A:1011942814300","article-title":"Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells","volume":"15","author":"Batrakova","year":"1998","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0115","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1023\/B:PHAM.0000036925.45002.a2","article-title":"Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block-Polycaprolactone amphiphilic diblock copolymers","volume":"21","author":"Zastre","year":"2004","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0120","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1023\/A:1011964213024","article-title":"Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers","volume":"15","author":"Batrakova","year":"1998","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/bc970118d","article-title":"Interactions of pluronic block copolymers with brain microvessel endothelial cells: Evidence of two potential pathways for drug absorption","volume":"8","author":"Miller","year":"1997","journal-title":"Bioconjug Chem"},{"key":"10.1002\/jps.21723_bb0130","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1002\/jps.21372","article-title":"Interactions of pluronic block copolymers on P-gp efflux activity: Experience with HIV-1 protease inhibitors","volume":"97","author":"Shaik","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21723_bb0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0165-022X(95)00032-M","article-title":"Determination of surfactant critical micelle concentration by a novel fluorescence depolarization technique","volume":"31","author":"Zhang","year":"1996","journal-title":"J Biochem Biophys Methods"},{"key":"10.1002\/jps.21723_bb0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/13550289909021992","article-title":"CNS as an HIV-1 reservoir; BBB and drug delivery","volume":"5","author":"Kerza-Kwiatecki","year":"1999","journal-title":"J Neurovirol"},{"key":"10.1002\/jps.21723_bb0145","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.1996.14.2.610","article-title":"Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer","volume":"14","author":"Boote","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1002\/jps.21723_bb0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00280-004-0854-6","article-title":"A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors","volume":"55","author":"Planting","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/jps.21723_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0169-409X(02)00176-X","article-title":"Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier","volume":"55","author":"Kabanov","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21723_bb0160","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1023\/A:1015000503629","article-title":"Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS)","volume":"16","author":"Dintaman","year":"1999","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0165","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1111\/j.1742-4658.2007.06140.x","article-title":"Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane","volume":"274","author":"Regev","year":"2007","journal-title":"FEBS J"},{"key":"10.1002\/jps.21723_bb0170","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ymthe.2005.07.701","article-title":"Transcriptional activation of gene expression by pluronic block copolymers in stably and transiently transfected cells","volume":"13","author":"Sriadibhatla","year":"2006","journal-title":"Mol Ther"},{"key":"10.1002\/jps.21723_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/mp050050g","article-title":"Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85","volume":"3","author":"Batrakova","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.21723_bb0180","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1023\/A:1018942823676","article-title":"Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells","volume":"16","author":"Batrakova","year":"1999","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0185","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1128\/AAC.46.11.3456-3462.2002","article-title":"Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2)","volume":"46","author":"Williams","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21723_bb0190","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-3565(24)29254-5","article-title":"Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of energy depletion and membrane fluidization","volume":"299","author":"Batrakova","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.21723_bb0195","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1517\/13543784.7.9.1453","article-title":"Block copolymeric biotransport carriers as versatile vehicles for drug delivery","volume":"7","author":"Alakhov","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1002\/jps.21723_bb0200","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1021\/ma991634x","article-title":"Relationship between pluronic block copolymer structure, critical micellization concentration and partitioning coefficients of low molecular mass solutes","volume":"33","author":"Kozlov","year":"2000","journal-title":"Macromolecules"},{"key":"10.1002\/jps.21723_bb0205","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/jpet.102.043307","article-title":"Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells","volume":"304","author":"Batrakova","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.21723_bb0210","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1023\/A:1026179132599","article-title":"Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85","volume":"20","author":"Batrakova","year":"2003","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21723_bb0215","doi-asserted-by":"crossref","first-page":"12053","DOI":"10.1021\/bi001038r","article-title":"Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line","volume":"39","author":"Lobert","year":"2000","journal-title":"Biochemistry"},{"key":"10.1002\/jps.21723_bb0220","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1124\/dmd.107.017723","article-title":"P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution","volume":"35","author":"Shaik","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.21723_bb0225","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/bc950093n","article-title":"Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer","volume":"7","author":"Alakhov","year":"1996","journal-title":"Bioconjug Chem"},{"key":"10.1002\/jps.21723_bb0230","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/jnci\/85.20.1685","article-title":"Measurement of cremophor EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype","volume":"85","author":"Webster","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/jps.21723_bb0235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00280-001-0394-2","article-title":"Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut","volume":"49","author":"Bardelmeijer","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/jps.21723_bb0240","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1054\/bjoc.2001.2118","article-title":"The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients","volume":"85","author":"Malingre","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1002\/jps.21723_bb0245","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00003088-200342070-00005","article-title":"Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy","volume":"42","author":"ten Tije","year":"2003","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915329439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915329439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T10:23:51Z","timestamp":1739010231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915329439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0022354915329439"],"URL":"https:\/\/doi.org\/10.1002\/jps.21723","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}